| Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis |
52 |
| Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma |
46 |
| Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study |
30 |
| Knockdown of LncRNA ANRIL suppresses cell proliferation, metastasis, and invasion via regulating miR-122-5p expression in hepatocellular carcinoma |
30 |
| Microarray profiles reveal that circular RNA hsa_circ_0007385 functions as an oncogene in non-small cell lung cancer tumorigenesis |
30 |
| Melanoma treatment: from conventional to nanotechnology |
23 |
| Novel positioning from obesity to cancer: FTO, an m(6)A RNA demethylase, regulates tumour progression |
22 |
| Computer-assisted medical image classification for early diagnosis of oral cancer employing deep learning algorithm |
20 |
| FTIR-based spectrum of salivary exosomes coupled with computational-aided discriminating analysis in the diagnosis of oral cancer |
20 |
| MicroRNAs in regulation of triple-negative breast cancer progression |
19 |
| Long non-coding RNA H19 promotes glucose metabolism and cell growth in malignant melanoma via miR-106a-5p/E2F3 axis |
19 |
| Targeting LC3 and Beclin-1 autophagy genes suppresses proliferation, survival, migration and invasion by inhibition of Cyclin-D1 and uPAR/Integrin beta 1/ Src signaling in triple negative breast cancer cells |
18 |
| The NF-kappa B signalling pathway in colorectal cancer: associations between dysregulated gene and miRNA expression |
17 |
| Role of ferroptosis in hepatocellular carcinoma |
17 |
| Mistletoe in oncological treatment: a systematic review Part 1: survival and safety |
16 |
| Circular RNAs: pivotal molecular regulators and novel diagnostic and prognostic biomarkers in non-small cell lung cancer |
15 |
| Prognostic relevance of programmed cell death-ligand 1 expression and CD8+TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy |
15 |
| Therapeutic potential of GSK-J a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia |
15 |
| Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma |
15 |
| Immune checkpoint inhibitor therapy and myocarditis: a systematic review of reported cases |
15 |
| Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice |
15 |
| TP53 mutations as potential prognostic markers for specific cancers: analysis of data from The Cancer Genome Atlas and the International Agency for Research on Cancer TP53 Database |
14 |
| Microbiota in cancer development and treatment |
14 |
| Long-term efficacy of ultrasound-guided low power microwave ablation for the treatment of primary papillary thyroid microcarcinoma: a 3-year follow-up study |
14 |
| Feasibility and safety of nivolumab in advanced hepatocellular carcinoma: real-life experience from three German centers |
14 |
| METase/lncRNA HULC/FoxM1 reduced cisplatin resistance in gastric cancer by suppressing autophagy |
14 |
| Mistletoe in oncological treatment: a systematic review: Part2: quality of life and toxicity of cancer treatment |
13 |
| Radiomics-based machine learning methods for isocitrate dehydrogenase genotype prediction of diffuse gliomas |
13 |
| DNA methylation profiling distinguishes Ewing-like sarcoma with EWSR1-NFATc2 fusion from Ewing sarcoma |
13 |
| Cancer-associated fibroblasts promote gastric tumorigenesis through EphA2 activation in a ligand-independent manner |
12 |
| A study of association of Oncotype DX recurrence score with DCE-MRI characteristics using multivariate machine learning models |
12 |
| Iron oxide-gold core-shell nano-theranostic for magnetically targeted photothermal therapy under magnetic resonance imaging guidance |
12 |
| Estrogen receptor beta increases sensitivity to enzalutamide in androgen receptor-positive triple-negative breast cancer |
12 |
| The heat shock protein 47 as a potential biomarker and a therapeutic agent in cancer research |
12 |
| High-intensity exercise interventions in cancer survivors: a systematic review exploring the impact on health outcomes |
12 |
| Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers |
12 |
| Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials |
11 |
| PLK4: a promising target for cancer therapy |
11 |
| The role of dietary phytochemicals in the carcinogenesis via the modulation of miRNA expression |
11 |
| Moderate versus extreme hypofractionated radiotherapy: a toxicity comparative analysis in low- and favorable intermediate-risk prostate cancer patients |
11 |
| Prognostic role of glycolysis for cancer outcome: evidence from 86 studies |
11 |
| CD LAG and IDO1 expressions in tumor-infiltrating immune cells as prognostic biomarker for patients with MSI-high colon cancer |
11 |
| Role of natural killer cells in lung cancer |
11 |
| Long non-coding RNA HOTTIP affects renal cell carcinoma progression by regulating autophagy via the PI3K/Akt/Atg13 signaling pathway |
11 |
| Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group |
11 |
| MicroRNA-338-5p plays a tumor suppressor role in glioma through inhibition of the MAPK-signaling pathway by binding to FOXD1 |
11 |
| Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings |
11 |
| Clinical significance of circulatory microRNA-203 in serum as novel potential diagnostic marker for multiple myeloma |
10 |
| C-reactive protein as an early marker of immune-related adverse events |
10 |
| Patterns of breast cancer relapse in accordance to biological subtype |
10 |
